Ledingham, K.; Hinchliffe, S.; Jackson, M.; Thomas, F.; Tomson, G.. Antibiotic Resistance: Using a Cultural Contexts of Health Approach to Address a Global Health Challenge; World Health Organization, 2019.
Lakhundi, S.; Zhang, K. Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology. Clin. Microbiol. Rev. 2018, 31 (4), e00020-18, 10.1128/CMR.00020-18
Miller, W. R.; Murray, B. E.; Rice, L. B.; Arias, C. A. Vancomycin-Resistant Enterococci: Therapeutic Challenges in the 21st Century. Infect. Dis. Clin. North Am. 2016, 30 (2), 415-439, 10.1016/j.idc.2016.02.006
Rossolini, G. M.; Arena, F.; Pecile, P.; Pollini, S. Update on the Antibiotic Resistance Crisis. Curr. Opin. Pharmacol. 2014, 18, 56-60, 10.1016/j.coph.2014.09.006
Cassini, A.; Högberg, L. D.; Plachouras, D.; Quattrocchi, A.; Hoxha, A.; Simonsen, G. S.; Colomb-Cotinat, M.; Kretzschmar, M. E.; Devleesschauwer, B.; Cecchini, M. et al. Attributable Deaths and Disability-Adjusted Life-Years Caused by Infections with Antibiotic-Resistant Bacteria in the EU and the European Economic Area in 2015: A Population-Level Modelling Analysis. Lancet Infect. Dis. 2019, 19 (1), 56-66, 10.1016/S1473-3099(18)30605-4
Docquier, J.-D.; Mangani, S. An Update on β-Lactamase Inhibitor Discovery and Development. Drug Resist. Updates 2018, 36, 13-29, 10.1016/j.drup.2017.11.002
Tacconelli, E.; Magrini, N. Global Priority List of Antibiotic-resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics; World Health Organization, https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf, accessed December 18, 2019.
David, M. Z.; Dryden, M.; Gottlieb, T.; Tattevin, P.; Gould, I. M. Recently Approved Antibacterials for Methicillin-Resistant Staphylococcus aureus (MRSA) and Other Gram-Positive Pathogens: The Shock of the New. Int. J. Antimicrob. Agents 2017, 50 (3), 303-307, 10.1016/j.ijantimicag.2017.05.006
Lee, Y. R.; Burton, C. E. Eravacycline, a Newly Approved Fluorocycline. Eur. J. Clin. Microbiol. Infect. Dis. 2019, 38 (10), 1787-1794, 10.1007/s10096-019-03590-3
Liu, B.; Trout, R. E. L.; Chu, G.-H.; McGarry, D.; Jackson, R. W.; Hamrick, J.; Daigle, D.; Cusick, S.; Pozzi, C.; De Luca, F. Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine-and Metallo-β-Lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J. Med. Chem. 2019, 10.1021/acs.jmedchem.9b01518
Hamrick, J. C.; Docquier, J.-D.; Uehara, T.; Myers, C. L.; Six, D. A.; Chatwin, C. L.; John, K. J.; Vernacchio, S. F.; Cusick, S. M.; Trout, R. E. L. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine-and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2020, 10.1128/AAC.01963-19
Castanheira, M.; Lindley, J.; Huynh, H.; Mendes, R. E.; Lomovskaya, O. 677. Activity of Novel β-Lactamase Inhibitor QPX7728 Combined with β-Lactam Agents When Tested Against Carbapenem-Resistant Enterobacteriaceae (CRE) Isolates. Open Forum Infect. Dis. 2019, 6 (Suppl 2), S309, 10.1093/ofid/ofz360.745
Marcoccia, F. Interaction of the Metallo β-Lactamase Inhibitor ANT2681 with NDM-Type Enzymes Shows a pH Dependent Potency and in vitro Antibacterial Activity. ASM Microbe 2019, San Francisco, June 20-24, 2019; Abstract 2019-LB-6853; ASM Press: Washington, DC, 2019.
Thee, S.; Garcia-Prats, A. J.; Donald, P. R.; Hesseling, A. C.; Schaaf, H. S. Fluoroquinolones for the Treatment of Tuberculosis in Children. Tuberculosis (Oxford, U. K.) 2015, 95 (3), 229-245, 10.1016/j.tube.2015.02.037
Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48 (1), 1-12, 10.1086/595011
Wright, G. D. Antibiotic Adjuvants: Rescuing Antibiotics from Resistance. Trends Microbiol. 2016, 24 (11), 862-871, 10.1016/j.tim.2016.06.009
Corbett, D.; Wise, A.; Langley, T.; Skinner, K.; Trimby, E.; Birchall, S.; Dorali, A.; Sandiford, S.; Williams, J.; Warn, P. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Antimicrob. Agents Chemother. 2017, 61 (8), e00200-17, 10.1128/AAC.00200-17
Eckburg, P. B.; Lister, T.; Walpole, S.; Keutzer, T.; Utley, L.; Tomayko, J.; Kopp, E.; Farinola, N.; Coleman, S. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects. Antimicrob. Agents Chemother. 2019, 63 (9), 00892-19, 10.1128/AAC.00892-19
Cui, P.; Niu, H.; Shi, W.; Zhang, S.; Zhang, H.; Margolick, J.; Zhang, W.; Zhang, Y. Disruption of Membrane by Colistin Kills Uropathogenic Escherichia coli Persisters and Enhances Killing of Other Antibiotics. Antimicrob. Agents Chemother. 2016, 60 (11), 6867-6871, 10.1128/AAC.01481-16
Hall, M. J.; Middleton, R. F.; Westmacott, D. The Fractional Inhibitory Concentration (FIC) Index as a Measure of Synergy. J. Antimicrob. Chemother. 1983, 11 (5), 427-433, 10.1093/jac/11.5.427
EUCAST: Clinical breakpoints and dosing of antibiotics, http://www.eucast.org/clinical_breakpoints/ (accessed Dec 31, 2019).
D'Andrea, M. M.; Giani, T.; D'Arezzo, S.; Capone, A.; Petrosillo, N.; Visca, P.; Luzzaro, F.; Rossolini, G. M. Characterization of PABVA01, a Plasmid Encoding the OXA-24 Carbapenemase from Italian Isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 2009, 53 (8), 3528-3533, 10.1128/AAC.00178-09
Guerrini, V.; De Rosa, M.; Pasquini, S.; Mugnaini, C.; Brizzi, A.; Cuppone, A. M.; Pozzi, G.; Corelli, F. New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains. Tuberculosis 2013, 93, 405-411, 10.1016/j.tube.2013.02.017
Pasquini, S.; De Rosa, M.; Pedani, V.; Mugnaini, C.; Guida, F.; Luongo, L.; De Chiaro, M.; Maione, S.; Dragoni, S.; Frosini, M.; Ligresti, A.; Di Marzo, V.; Corelli, F.-Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Anti-Hyperalgesic Effects in Mice. J. Med. Chem. 2011, 54, 5444-5453, 10.1021/jm200476p
Artico, M.; Corelli, F.; Massa, S.; Stefancich, G.; Panico, S.; Simonetti, N. Studies on antibacterial and antifungal agents. Note VI. Pirfloxacin and related compounds: synthetic and microbiological studies. Farmaco, Ed. Sci. 1986, 4, 366-380
Mugnaini, C.; Brizzi, A.; Ligresti, A.; Allarà, M.; Lamponi, S.; Vacondio, F.; Silva, C.; Mor, M.; Di Marzo, V.; Corelli, F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. J. Med. Chem. 2016, 59, 1052-1067, 10.1021/acs.jmedchem.5b01559
Brizzi, A.; Brizzi, V.; Cascio, M. G.; Bisogno, T.; Sirianni, R.; Di Marzo, V. Design, Synthesis, and Binding Studies of New Potent Ligands of Cannabinoid Receptors. J. Med. Chem. 2005, 48, 7343-7350, 10.1021/jm0501533
Brizzi, A.; Cascio, M. G.; Brizzi, V.; Bisogno, T.; Dinatolo, M. T.; Martinelli, A.; Tuccinardi, T.; Di Marzo, V. Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors. Bioorg. Med. Chem. 2007, 15, 5406-5416, 10.1016/j.bmc.2007.05.060
Brizzi, A.; Brizzi, V.; Cascio, M. G.; Corelli, F.; Guida, F.; Ligresti, A.; Maione, S.; Martinelli, A.; Pasquini, S.; Tuccinardi, T.; Di Marzo, V. New Resorcinol-Anandamide "Hybrids" as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo. J. Med. Chem. 2009, 52, 2506-2514, 10.1021/jm8016255
Brizzi, A.; Aiello, F.; Marini, P.; Cascio, M. G.; Corelli, F.; Brizzi, V.; De Petrocellis, L.; Ligresti, A.; Luongo, L.; Lamponi, S.; Maione, S.; Pertwee, R. G.; Di Marzo, V. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: identification of a dual cannabinoid receptor/TRPA1 channel agonist. Bioorg. Med. Chem. 2014, 22, 4770-4783, 10.1016/j.bmc.2014.07.006
Massa, S.; Mai, A.; Artico, M.; Corelli, F. Heterocyclic system. XI. Synthesis of 1 H,4 H-pyrazolo[4,3-b]pyrrolizine and 2 H,4 H-pyrazolo[4,3-b]pyrrolizine derivatives. J. Heterocycl. Chem. 1990, 27, 1805-1808, 10.1002/jhet.5570270653
Silvestri, R.; Cascio, M. G.; La Regina, G.; Piscitelli, F.; Lavecchia, A.; Brizzi, A.; Pasquini, S.; Botta, M.; Novellino, E.; Di Marzo, V.; Corelli, F. Synthesis, Cannabinoid Receptor Affinity, and Molecular Modeling Studies of Substituted 1-Aryl-5-(1 H-pyrrol-1-yl)-1 H-pyrazole-3-carboxamides. J. Med. Chem. 2008, 51, 1560-1576, 10.1021/jm070566z
Hotinski, A. K.; Lewis, I. D.; Ross, D. M. Vosaroxin Is a Novel Topoisomerase-II Inhibitor with Efficacy in Relapsed and Refractory Acute Myeloid Leukaemia. Expert Opin. Pharmacother. 2015, 16 (9), 1395-1402, 10.1517/14656566.2015.1044437
